


# PCCP

Physical Chemistry Chemical Physics  
rsc.li/pccp



ISSN 1463-9076



ROYAL SOCIETY  
OF CHEMISTRY

**PAPER**

Nicholas Cox *et al.*

Solvent water interactions within the active site of the membrane type I matrix metalloproteinase



Cite this: *Phys. Chem. Chem. Phys.*, 2017, 19, 30316

# Solvent water interactions within the active site of the membrane type I matrix metalloproteinase†

Elena Decaneto,<sup>‡,ab</sup> Tatiana Vasilevskaya,<sup>‡,c</sup> Yuri Kutin,<sup>‡,a</sup> Hideaki Ogata,<sup>‡,a</sup> Moran Grossman,<sup>b</sup> Irit Sagi,<sup>d</sup> Martina Havenith,<sup>b</sup> Wolfgang Lubitz,<sup>‡,a</sup> Walter Thiel<sup>‡,c</sup> and Nicholas Cox<sup>‡,ae</sup>

Matrix metalloproteinases (MMP) are an important family of proteases which catalyze the degradation of extracellular matrix components. While the mechanism of peptide cleavage is well established, the process of enzyme regeneration, which represents the rate limiting step of the catalytic cycle, remains unresolved. This step involves the loss of the newly formed N-terminus (amine) and C-terminus (carboxylate) protein fragments from the site of catalysis coupled with the inclusion of one or more solvent waters. Here we report a novel crystal structure of membrane type I MMP (MT1-MMP or MMP-14), which includes a small peptide bound at the catalytic Zn site via its C-terminus. This structure models the initial product state formed immediately after peptide cleavage but before the final proton transfer to the bound amine; the amine is not present in our system and as such proton transfer cannot occur. Modeling of the protein, including earlier structural data of Bertini and coworkers [I. Bertini, *et al.*, *Angew. Chem., Int. Ed.*, 2006, **45**, 7952–7955], suggests that the C-terminus of the peptide is positioned to form an H-bond network to the amine site, which is mediated by a single oxygen of the functionally important Glu240 residue, facilitating efficient proton transfer. Additional quantum chemical calculations complemented with magneto-optical and magnetic resonance spectroscopies clarify the role of two additional, non-catalytic first coordination sphere waters identified in the crystal structure. One of these auxiliary waters acts to stabilize key intermediates of the reaction, while the second is proposed to facilitate C-fragment release, triggered by protonation of the amine. Together these results complete the enzymatic cycle of MMPs and provide new design criteria for inhibitors with improved efficacy.

Received 15th August 2017,  
Accepted 14th September 2017

DOI: 10.1039/c7cp05572b

rsc.li/pccp

<sup>a</sup> Max Planck Institute for Chemical Energy Conversion, Stiftstraße. 34-36, D-45470, Mülheim an der Ruhr, Germany. E-mail: nicholas.cox@cec.mpg.de

<sup>b</sup> Department of Physical Chemistry II, Ruhr-Universität Bochum, 44780 Bochum, Germany

<sup>c</sup> Max-Planck-Institut für Kohlenforschung, Kaiser-Wilhelm-Platz 1, D-45470, Mülheim an der Ruhr, Germany

<sup>d</sup> Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel

<sup>e</sup> Research School of Chemistry, Australian National University, Canberra, ACT 2601, Australia. E-mail: nick.cox@anu.edu.au

† Electronic supplementary information (ESI) available: (S1) Expression and purification of the active catalytic domain of MT1-MMP; (S2) molar extinction coefficient determination for wild type MT1-MMP; (S3) preparation of apo-MT1-MMP (metal-free material)/preparation of Co<sup>2+</sup>-MT1-MMP; (S4) inhibition of Co<sup>2+</sup>-MT1-MMP by acetohydroxamic acid (AHA); (S5) X-ray data-collection statistics for MT1-MMP; (S6) additional crystallographic figures. Comparison of the X-ray structure of MT1-MMP to literature MMP structures; (S7) analysis of Co<sup>2+</sup> EPR and MCD spectra from wild type and inhibited Co<sup>2+</sup>-MT1-MMP; (S8) QM/MM geometry optimizations of structural models A-K; (S9) comparison of computed key distances in Co<sup>2+</sup> and Zn<sup>2+</sup> QM/MM models; (S10) optimized QM/MM geometries (QM part); (S11) optimized model geometries used for EPR parameter calculations; (S12) calibration of computed cobalt isotropic hyperfine coupling constants; (S13) references. See DOI: 10.1039/c7cp05572b

‡ ED (biochemistry), TV (computations), YK (EPR) and HO (crystallography) made complementary and equal contributions to the manuscript.

## 1. Introduction

The membrane type I matrix metalloproteinase (MT1-MMP or MMP-14) is a zinc-dependent transmembrane endopeptidase that plays a major role in regulation of cellular migration and in the degradation and remodeling of extracellular matrix components, such as type I, II, III collagens, fibronectin, gelatin and proteoglycans.<sup>1,2</sup> In recent years, interest in MT1-MMP has increased following observations that high expression levels of MT1-MMP are also associated with tumor progression and metastasis.<sup>3,4</sup> An inhibitor candidate that meets pharmaceutically required specificity and affinity has yet to be identified.<sup>5,6</sup>

The MMP family of proteins has been extensively studied. The catalytic Zn<sup>2+</sup> ion is located near the protein surface, with the cleft above the metal site allowing binding of substrate peptides. In its resting state the Zn ion is coordinated by three His residues (His239, His243, His249 for MT1-MMP) and at least one water molecule which serves as the nucleophile during substrate hydrolysis.<sup>7,8</sup> Mechanistic studies at close-to-neutral pH revealed that this water molecule is strongly polarized forming a bridge between the conserved glutamate base (Glu240) and the Lewis acidic Zn.<sup>9–11</sup>






Fig. 1 (a) Proposed catalytic mechanism of peptide hydrolysis of MMPs; (b) schematic illustration of the binding features of an acetohydroxamic acid (AHA) molecule to the catalytic zinc of MMPs.

A four-step catalytic mechanism of peptide hydrolysis has been proposed for MMPs.<sup>7,12–14</sup> Upon peptide docking (Fig. 1a, ES, 1) the reaction starts with the nucleophilic attack of the carbonyl carbon of the scissile bond by the catalytic water molecule. The side chain of Glu240 acts as a proton shuttle, transferring a proton of the glutamate-polarized water to the nitrogen atom of the scissile amide forming a metal penta-coordinated intermediate complex (ES<sup>‡</sup>, 2). The deprotonated water nucleophile then attacks the C–O bond of the peptide leading to cleavage of the C–N bond (3). This step is coupled to or followed by the transfer of the second water-derived proton to the amine group *via* the glutamate base. Theoretical modeling suggests that a second auxiliary solvent water molecule acts as an electrophile, stabilizing the newly formed carboxylate product.<sup>7</sup> The last step corresponds to the release of the carboxylate product and the re-uptake of a water molecule. (Fig. 1a, 4).

Crystallographic characterization of the intermediates of the reaction cycle has thus far been elusive. Bertini *et al.*<sup>15</sup> have reported structures of two different MMPs where substrate was present, capturing the cleaved peptide fragments in the catalytic pocket. These are the earliest intermediates that can be characterized suggesting that the catalytic steps (Fig. 1a, 2, 3) are fast and the rate-limiting step instead represents product release (Fig. 1a, 4). This is in agreement with steady-state and pre-steady-state kinetics data from the tumor necrosis factor- $\alpha$  converting enzyme (TACE),<sup>16</sup> another member of the MMP family.

In addition, computational studies suggest that the loss of the bidentate C-terminus fragment from the Zn<sup>2+</sup> during (Fig. 1a, 4) is the rate limiting step with an estimated barrier of 20 kcal mol<sup>−1</sup>,<sup>13</sup> however this intermediate has yet to be characterized. The large barrier is derived from the negatively charged C-fragment coordinating the positive Zn<sup>2+</sup> ion in a bidentate fashion. It is also not clear in what order the peptide fragments are released. The study by Bertini *et al.*<sup>15</sup> characterized an intermediate with both C- and N-fragment in the catalytic pocket and a second intermediate with only the N-fragment suggesting, surprisingly, that C-fragment dissociation occurs before N-fragment dissociation. This has led to a concerted mechanism being proposed involving partial carboxylate detachment to initiate N-fragment release, coupled with solvent water insertion.

Pinpointing the protein structural elements that foster this progression has been challenging. Point mutations are found to strongly affect the rate of catalysis,<sup>17</sup> particularly when replacing the glutamate base;<sup>18</sup> however, as the relevant mutated residues are implicated in both the hydrolysis and product release steps, their precise role in enzyme reactivation is unclear. The role of auxiliary/solvent water in product release is also not resolved, nor is there good experimental evidence for auxiliary water molecule(s) invoked in theoretical treatments of the catalytic cycle. This is mainly due to the difficulty of crystallizing the protein in its native form owing to autocatalysis. As a consequence, MMPs are typically crystallized in the presence of various inhibitors including: regulator proteins (TIMPs),<sup>19,20</sup> peptides and small synthetic molecules, such as hydroxamic acids, *e.g.* acetohydroxamic acid<sup>21</sup> (AHA, Fig. 1b) with the latter chelating the catalytic zinc ion displacing the water nucleophile.<sup>22</sup> To some extent the AHA-bound form of the enzyme models the ES<sup>‡</sup> intermediate, at least in terms of the coordination of the Zn ion. However, as these inhibitors are small, they can be removed after crystallization by extensive washing to at least allow the solvation of the Zn ion in its resting state to be examined as achieved in the study of Bertini.<sup>15</sup> Using this approach, both MMP-8 and MMP-12 have been characterized leading to two different descriptions of the resting state solvation sphere. In MMP-8 only one water ligand is resolved with full occupancy, while two further water molecules have only 20% occupancy. If the latter are neglected, the resulting geometry is a flattened tetrahedron. In contrast, the active site of MMP-12 contains three coordinating water molecules leading to an almost regular octahedral geometry of the Zn site.<sup>15</sup> For MT1-MMP, the system used in this study, only an X-ray structure with a TIMP has been reported.<sup>19,20</sup> The uninhibited coordination number has instead been inferred from stopped-flow X-ray absorption (XAS), which suggested that the metal is tetracoordinated, *i.e.* it only has one water ligand, the nucleophilic water.<sup>23</sup>

Regardless of the precise number of coordinating water molecules in the resting state, it is the presence of solvent in the ‘activated’ states of catalysis which is crucial to address function. Recent THz absorbance spectroscopy suggests that solvent water dynamics plays a crucial role for the enzymatic activity and protein recognition.<sup>23</sup> Here we report the crystal structure of the catalytic domain of human MT1-MMP with a



small peptide bound at its catalytic site, modeling the first product state after peptide cleavage. This novel structure identifies two auxiliary water molecules whose role in the enzymatic reaction was analyzed using optical, magnetic resonance and computational techniques. Together these data provide new information on the catalytic mechanism of MMPs and the importance of the immediate solvation sphere in directing catalysis.

## 2. Materials and methods

### 2.1 Preparation of Zn<sup>2+</sup> and Co<sup>2+</sup>-MT1-MMP

The procedure for the expression, purification and preparation of Zn<sup>2+</sup>- and Co<sup>2+</sup>-MT1-MMP is described in the ESI,† S1, S2 and S3. Metal content of protein samples was measured by atomic absorption spectroscopy (Mikrolab Kolbe GmbH, Mülheim/Ruhr, Germany). Unless otherwise stated, all spectroscopic measurements were performed at a protein concentration of 100–300 μM in 50 mM Hepes pH 7.4, 100 mM NaCl and 5 mM CaCl<sub>2</sub>. Inhibited samples contained additionally 0.5–1 M of aceto-hydroxamic acid (AHA), (ESI,† S4). Inhibited samples were incubated for at least 2 hours in AHA prior to measurement. Low temperature measurements included glycerol in the buffer: 30% v/v for EPR, 80% v/v for MCD.

### 2.2 Enzymatic assays

Enzymatic assays were performed at 25 °C by monitoring the increase in fluorescence intensity of methoxycoumarin-4-acetyl (Mca) due to the decrease of FRET quenching by 2,4-dinitrophenyl (Dnp) upon hydrolysis of the fluorogenic peptide Mca-KPLGKK(Dnp)AR-NH<sub>2</sub><sup>24,25</sup> ( $\lambda_{\text{ex}}$ : 340 nm,  $\lambda_{\text{em}}$ : 400 nm) with a 96-well plate reader connected to a fluorescence spectrophotometer (Varian Cary Eclipse). The Michaelis-Menten constant for the hydrolysis of the collagen-like substrate was estimated by fitting the initial velocity (for the first  $\approx 100$  s) with the Michaelis-Menten equation  $v_i = v_{\text{max}}[S]/(K_M + [S])$ , where  $v_i$  is the initial rate (fluorescence unit per second),  $[S]$  is the substrate concentration (M),  $v_{\text{max}}$  is the maximum reaction rate attained at the saturating substrate concentration and  $K_M$  is the Michaelis-Menten constant.

### 2.3 Protein crystallography

Crystals were obtained from 10 mg ml<sup>-1</sup> of MT1-MMP using the sitting drop/vapor-diffusion method upon mixing with an equal volume of 0.2 M ammonium nitrate, 20% (w/v) PEG 3350 (pH 6.2).<sup>26</sup> For X-ray diffraction experiments, the crystals were soaked in buffer containing 0.3 M ammonium nitrate, 25% (w/v) PEG 3350 (pH 6.2) and 20% glycerol as a cryoprotectant. Diffraction data sets were collected on beamline BL14.2 at BESSYII (Helmholtz-Zentrum Berlin, Germany). A complete native data set was collected to 2.24 Å resolution at an X-ray wavelength of 0.91841 Å (PDB entry 5H0U). Diffraction images were indexed, integrated and scaled using the program XDS.<sup>27</sup> The molecular replacement method was applied using the program MOLREP<sup>28</sup> and the coordinates of the MT1-MMP-TIMP2 complex (PDB entry 1BQQ)<sup>19</sup> were used

as an initial search model. Refinement was carried out by the program PHENIX.REFINE.<sup>29</sup> The stereochemical properties were checked by RAMPAGE.<sup>30</sup> Data collection and refinement statistics are listed in the ESI,† S5.

### 2.4 Room temperature absorption and MCD measurements

Electronic absorption spectra were recorded with a Cary Model 50 Spectrophotometer. MCD spectra were recorded with 1 nm bandwidth on a Jasco J-715 spectropolarimeter. The 1 cm pathlength quartz cuvette was inserted in a permanent magnet of 1.4 T field strength (Olis, Inc., Atlanta, GA). MCD spectra were collected to estimate the molar extinction coefficient of wild type MT1-MMP using the protein's tryptophan residues.<sup>31,32</sup> A calibration curve was determined by measuring MCD spectra of different concentrations (25, 50, 75, 100, 150 and 200 μM) of L-tryptophan in 50 mM Tris (pH 7.4), 100 mM NaCl and 5 mM CaCl<sub>2</sub>. The MCD spectrum of 18 μM of MT1-MMP in the same buffer was acquired and compared with the calibration curve to calculate the molar extinction coefficient (ESI,† Fig. S2).

### 2.5 Low temperature MCD measurements

MCD experiments at low temperature were carried out with an Olis DSM17 CD spectropolarimeter while the sample was placed in the Oxford cryostat Spectromag SM4000. The temperature range was from 1.7 K to 20 K and the energy range from 33 330 cm<sup>-1</sup> (300 nm) to 12 500 cm<sup>-1</sup> (800 nm). The solutions were transferred to pre-cooled MCD holders with pre-cooled syringes, and then frozen in liquid nitrogen.

### 2.6 EPR measurements

X-band CW EPR measurements were performed in the temperature range of 5 to 20 K using a Bruker E500 spectrometer equipped with a Bruker ER 4116DM resonator, Oxford Instruments ESR 935 cryostat and ITC503 temperature controller. Microwave power levels used were in the range of 630 μW to 20 mW. Magnetic field modulation amplitude was 7.5 G. Q-band pulse EPR, ESEEM/HYSCORE and Davies ENDOR measurements were performed between 2 and 6.5 K using a Bruker ELEXSYS E580 Q-band pulse EPR/ENDOR spectrometer equipped with a home-built TE011 microwave resonator<sup>33</sup> and cryogen free variable temperature cryostat from Cryogenic Ltd.<sup>34</sup> The RF amplifier used for ENDOR measurements was AR 2500L (Amplifier Research). Field-swept EPR spectra were obtained *via* integration of the electron spin echo (ESE) signal. The length of the  $\pi$  pulse was 80 ns and the delay between the two pulses was 348 ns.

### 2.7 Setup of the computational model

To create an all-atom three-dimensional model of MT1-MMP, the initial coordinates of the heavy atoms were taken from the crystal structure. Other conceivable structures of metal coordination spheres at the structural and catalytic zinc sites were built using the Discovery Studio Visualizer. To model the inhibited enzyme, an acetohydroxamate molecule was manually inserted into the active site using the Discovery Studio Visualizer software, using the crystal structure of MMP-9 complexed with a



similar inhibitor (PDB ID: 2OW1)<sup>35</sup> as a guide. The model systems were solvated with 9678 water molecules using the VMD software<sup>36</sup> and equilibrated by means of 500 ps molecular dynamics (MD) simulations with periodic boundary conditions.

## 2.8 Molecular dynamics simulations

The CHARMM<sup>37</sup> force field was used for the protein atoms and the TIP3P model<sup>38</sup> for water. Electrostatic interactions were computed using the Particle-Mesh-Ewald method with a grid spacing of 1.0 Å. Electrostatic and van der Waals interactions were smoothly switched to zero between 10 and 12 Å. A temperature of 300 K was controlled with a Langevin thermostat. The bond lengths of water molecules were constrained using the SHAKE algorithm.<sup>39</sup> All MD simulations were carried out using the NAMD program.<sup>40</sup> During these classical MD simulations, the coordinates of amino acid side chains that form the coordination environment of both zinc ions were frozen, *i.e.* Asp71, His69, Thr73, His84, Tyr86, His97, His122, His126, and His132. This helped to prevent drastic reorganizations in the structural site (keeping the zinc coordination number of 4). At the catalytic site the zinc coordination number became 6 (3 histidine residues and 3 water molecules), which is favored due to the force field parameterization of the zinc ion. Thereafter the solvation water shell was reduced by keeping only water molecules within 12 Å from the protein. The subsequent MM minimization employed 1000 steepest-descent steps, 5000 conjugate-gradient steps, and 10 000 steps using the adopted basis Newton–Raphson method. During these minimizations, the atoms from the coordination environment of the two zinc ions were fixed. The resulting model systems were taken as starting structures for QM/MM calculations. In the studies on the Co-substituted enzyme, the metal was changed from zinc to cobalt.

## 2.9 QM/MM geometry optimizations

The QM region included the coordination sphere of the metal ions: the side chains of Asp71, His69, His84, His97, and the zinc/cobalt ion for the structural site; the side chains of His122, His126, His132, the acetate fragment of Glu123, the zinc/cobalt ion, 1–3 water/hydroxide ligands and/or an inhibitor for the catalytic site. The energy and gradients in the QM part were computed at the DFT level with the hybrid functional B3LYP<sup>41,42</sup> in combination with the 6-31G\*\* basis set.<sup>43</sup> The rest of the protein and the other water molecules constituted the MM region, which was described by the CHARMM force field. All reported calculations on the Co-substituted enzyme were done on the high-spin ( $S = 3/2$ ) state of Co<sup>2+</sup>. The QM/MM calculations were performed with the ChemShell software<sup>44,45</sup> using the TURBOMOLE 6.3 program<sup>46</sup> for the DFT calculations and the DL-POLY program<sup>47</sup> for the MM calculations. Geometries were optimized using hybrid delocalized internal coordinates.<sup>48</sup> The optimized region comprised all amino acid residues and water molecules containing atoms within a distance of 6 Å from any atom of the QM part; the rest of the protein and other solvent molecules were kept fixed. In all QM/MM calculations QM-MM electrostatic interactions were treated with electronic embedding

and without any cutoff for QM-MM electrostatics. The chosen QM/MM setup and protocol have been found to be adequate in a previous QM/MM study of the MMP-2 catalytic cycle.<sup>13</sup>

## 2.10 Property calculations

All single-point property calculations were carried out with the ORCA program<sup>49</sup> at QM(B3LYP/6-31G\*\*)/CHARMM optimized geometries. The hyperfine A tensor was obtained from single-point calculations with the meta-GGA TPSSh functional<sup>50</sup> and the triply polarized CP(PPP) basis set<sup>51</sup> on cobalt; the other atoms were described by the uncontracted def2-TZVP basis set.<sup>52,53</sup> We used an enhanced integration grid and integration accuracy of 11.0 for cobalt and of 9.0 for the cobalt-coordinating nitrogen atoms.<sup>51</sup> Scalar relativistic effects were accounted for by using the zeroth-order regular relativistic approximation (ZORA) methodology.<sup>54</sup> Point charges on the MM atoms were taken from the CHARMM force field. We calibrated the chosen QM(TPSSh/CP(PPP)) level of theory for the calculation of cobalt(II) isotropic hyperfine coupling constants against experimental data (ESI,† S12).

The state-averaged complete active space self-consistent field (SA-CASSCF) method was used for calculation of on-site zero-field splitting (ZFS) parameters and of d–d transitions in Co(II) coordination complexes. The active space in the SA-CASSCF calculations included seven electrons and five 3d-based molecular orbitals. 10 (18) roots were considered for the quartet (doublet) state. Dynamic correlation effects were included by using second-order *N*-electron valence perturbation theory (NEVPT2).<sup>55,56</sup> The ZORA Hamiltonian was employed in all these calculations, and the ZORA-recontracted version of the def2-TZVP basis set was used for all atoms. The spin–orbit coupling was represented by the spin–orbit mean field operator.<sup>57</sup>

# 3. Results and discussion

## 3.1 X-ray structure of catalytic domain of MT1-MMP

We report a high-resolution crystal structure of the catalytic domain of wild type MT1-MMP at a resolution of 2.2 Å<sup>26</sup> (Fig. 2 and ESI,† S5). Unlike previous crystallographic studies, no exogenous inhibitor (*e.g.* TIMPs, AHA) was included in the crystallization procedure. Globally, our MT1-MMP structure is similar to structures previously reported for MT1-MMP complexed with a TIMP-1 mutant<sup>20</sup> and TIMP-2.<sup>19</sup> No significant differences are seen in the surrounding of both the metal active site and the specificity pockets controlling substrate recognition, representing surface interactions in the immediate vicinity of the catalytic Zn site. The only exception was the conformation of the MT-Loop (Fig. 2). The MT-Loop is a region with the sequence <sup>163</sup>PYAPIREG<sup>170</sup> characteristic of MT-MMPs. While its function is not entirely clear, its deletion does not affect cell surface expression and proteolytic activity but does result in inefficient localization and pro-MMP-2 activation on the cell surface.<sup>58</sup> Recently, this region has been identified as an essential region to promote cellular invasion and a potential exosite target region to develop selective MT1-MMP inhibitors.<sup>59</sup> The different conformation of





Zn to some extent model this intermediate, with a two-oxygen bidentate ligand motif which corresponds to the peptide backbone oxygen and the water oxygen nucleophile. The structure reported in this study is different. It instead contains a bidentate carboxylate ligand, which is a product of the reaction. Indeed the first product intermediate proposed is that of a  $Zn^{2+}$  complexed with an asymmetric bidentate carboxylate ligand. Theoretical models predict that such a motif is stabilized by:<sup>7,12,13</sup>

(1) a hydrogen bond between the  $\alpha$  oxygen of the carboxylate and the transiently protonated Glu240 residue;

(2) a hydrogen bond between the  $\beta$  oxygen of the carboxylate and a near-by auxiliary water molecule, which acts as an electrophile.

Both of these features have been seen in crystal structures of MMPs;<sup>62–64</sup> in our structure the carboxylate C-terminus of the His-tag is in H-bonding distance to one oxygen of the Glu240 (2.6 Å) and an auxiliary water molecule, termed throughout this study as water in front ( $W_f$ ) as it is located on the front face of the Zn ion in the projection where the three His residues are located below the Zn and the Glu240 sits behind the Zn on the left hand side (Fig. 3 and 4a). A survey of all structures reveals that the presence of  $W_f$  is correlated with the asymmetric bidentate carboxylate ligand motif (Zn–O carboxylate distances of  $\approx 2.0$  and  $\approx 2.5$  Å). In the complete set of MMP structures with an exogenous carboxylate ligand, the carboxylate coordination mode is plastic, binding as a symmetric bidentate ligand all the way to a monodentate ligand, see ESI,† S6, Table S2.

The more novel feature of our crystal structure is an additional auxiliary water molecule, termed throughout this study as water back ( $W_b$ ) as it is located on the back face of the Zn ion. It interacts with both the  $Zn^{2+}$  ion and the 2nd coordination sphere proline residue. Such an auxiliary water molecule has only been observed once before, in a structure of MMP3 with a bound peptide.<sup>65</sup> This earlier structure, however, did not contain  $W_f$ , nor did it stabilize a bidentate motif for the carboxylate. It instead more closely resembled the 1st product state that could

be trapped in the study of Bertini, in which the carboxylate has already partially detached from the  $Zn^{2+}$  ion (mono-dentate).  $W_b$  in our structure is located such that it provides H-bonds to the  $\alpha$ -oxygen of the C-terminus, the same as  $W_f$ . Owing to its location near Glu240, it represents the best candidate to displace/replace the bound C-fragment. We hypothesize that this process is triggered upon proton transfer from the Glu240 to the amine, breaking the H-bond between the Glu240 and C-terminus. A small rearrangement of  $W_b$  can then act to recover the H-bond network between Glu240 and the C-fragment, stabilizing an intermediate containing a monodentate carboxylate ligand (see Section 4). Within this interpretation, the MMP3 structure<sup>65</sup> described above would then be representative of a later timepoint in this progression.

Lastly, we note that the position of the C-terminus/Glu240 couple in our structure also provides insight into how the C-fragment and N-fragment of the hydrolysis reaction likely interact immediately after peptide cleavage. The existing crystal structure of Bertini *et al.* locates the position of N-fragment (IAG) after the hydrolysis reaction. In our structure additional electron density is seen in approximately the same region, which we assigned to two cryoprotectant (glycerol) molecules. If instead this density is fitted to the IAG molecule, which is approximately the same size, the position of the amine head group in the 1st product state can be proposed. The nitrogen of the amine is within H-bonding distance of both the C-terminus ( $O_\alpha$ ) and the Glu240 (both 2.7 Å). We also note that in this model the Glu240 interacts with both the N-terminus and C-terminus fragments *via* a single oxygen (Fig. 4b). This is the same orientation for the Glu240 as seen in the earlier Bertini structures and in other MMPs with bound carboxylates (ESI,† S5 and S6). This is an important deviation from theoretical models of the first product state, which have instead assumed that the C- and N-fragments interact *via* a bidentate Glu240 (Fig. 4c) as is proposed for the gem-diol intermediate state. This result then implies that for the last proton transfer event, involving proton shuttling between




Fig. 4 (a) Modeled position of a putative N-fragment associated with the catalytic site (stereoview). The position of the N-fragment (IAG) was reoptimized from the structure(s) of Bertini *et al.*<sup>15</sup> in the location of cryoprotectant molecules seen in our structure. (b and c) Possible proton transfer intermediates, with model b consistent with our crystallographic data.




the transiently protonated Glu240 and the amine, only requires one oxygen (the protonated one) of the Glu240, as recently suggested by Vasilevskaya *et al.*,<sup>13</sup> making good chemical sense in so far that the proton transfer distance is significantly decreased using this motif.

### 3.3 Detecting interactions between the auxiliary/solvent water and cofactor throughout the catalytic cycle – replacement of the spectroscopically silent Zn<sup>2+</sup> ion with Co<sup>2+</sup>

Magnetic spectroscopic techniques, such as electron paramagnetic resonance (EPR) and magnetic circular dichroism (MCD), are valuable biophysical tools for the study of metalloproteins allowing the local structure (coordinating ligands), global structure (protein conformation) and catalytic mechanism to be examined in detail, under conditions similar to the physiological environment.<sup>66–68</sup> Although Zn<sup>2+</sup> is a d<sup>10</sup> closed shell ion and thus magnetically silent, magnetic spectroscopic studies can be made possible by replacing it with Co<sup>2+</sup>, which is instead a paramagnetic d<sup>7</sup> ion. Co<sup>2+</sup> is used in preference to other transition metals owing to its size and coordination chemistry being similar to Zn<sup>2+</sup> with earlier literature studies demonstrating Zn/Co exchange does not significantly affect protein activity.<sup>66–68</sup>

Importantly, for MMP homologues (*e.g.* MMP-1 and MMP-12) Zn/Co replacement does not change the coordination number/geometry of the active site.<sup>69,70</sup> The protocol for replacing the “spectroscopically silent” Zn<sup>2+</sup> ions in MT1-MMP with Co<sup>2+</sup> is described in the ESI,<sup>†</sup> S3. The modified enzyme is fully active as demonstrated with a standard assay developed for MMPs based on a FRET mechanism.<sup>24,25</sup> In this assay, the consumption of a fluorogenic collagen-like peptide leads to an increase of fluorescence at 400 nm allowing the reaction kinetics to be monitored. Interestingly the cobalt enzyme has a lower substrate turnover frequency of approximately 20% and a 2 fold increase of the Michaelis Menten constant  $K_M$ , ( $36 \pm 15$  vs.  $85 \pm 8$   $\mu\text{M}$ , Fig. 5A and B). The increase in  $K_M$  can be interpreted in a number of ways. As the rate limiting step of the reaction is the loss of the two peptide fragments from the protein cavity, the simplest enzymatic model requires four states (see Fig. 1): (i) free enzyme (E) + substrate (S); (ii) the enzyme–substrate complex (ES); (iii) the enzyme–product complex (EI); and (iv) free enzyme + product(s). Such a scenario can still be rationalized within the Michaelis Menten model, but  $K_M$  includes a pre-factor ( $K_M'$ ) which takes into account the product dissociation step.



$$K_M' = \frac{k_3}{k_2 + k_3} \cdot K_M = \frac{k_3}{k_2 + k_3} \cdot \frac{k_2 + k_{-1}}{k_1} \quad (2)$$

$$\frac{K_M'(\text{Zn})}{K_M'(\text{Co})} = \frac{k_3(\text{Zn})}{k_3(\text{Co})} \cdot \frac{k_2 + k_3(\text{Zn})}{k_2 + k_3(\text{Co})} \approx \frac{k_3(\text{Zn})}{k_3(\text{Co})} \quad (3)$$

Making the approximation that we only need to consider the effect of Zn/Co exchange on the rate determining step ( $k_3$ ), a simple formula for the ratio of  $K_M'$  for the Zn and Co enzymes can be obtained, *i.e.* we assume that all rates other than  $k_3$  are




Fig. 5 (A) Hydrolysis of a fluorogenic collagen-like peptide by Zn<sup>2+</sup>-MT1-MMP (blue) and Co<sup>2+</sup>-MT1-MMP (red). (B) Michaelis Menten constant  $K_M$  was obtained for the hydrolysis of different concentrations of the substrate using 0.5  $\mu\text{M}$  Co<sup>2+</sup>-MT1-MMP in 50 mM. Data were fitted with the Michaelis Menten equation ( $R^2 = 0.995$ ).

approximately the same. Similarly, as  $k_2$ , the hydrolysis reaction rate, is expected to be fast [ $k_2 \gg k_3(\text{Co}) \approx k_3(\text{Zn})$ ], the second term of eqn (3) is approximately 1, and thus the change in  $K_M'$  directly corresponds to the change in  $k_3$ . The rate of product dissociation is therefore estimated to be  $\approx 2$  fold slower for the Co<sup>II</sup> enzyme. We note that synthetic inhibitors such as AHA also successfully inhibit the Co<sup>2+</sup> enzyme (ESI,<sup>†</sup> S4) with similar  $K_D$  values, *i.e.* 10–20 mM.<sup>71–73</sup>

### 3.4 Dynamic interactions of auxiliary waters: electronic absorption and low temperature MCD of Co<sup>2+</sup>-MT1-MMP

Electronic absorption spectra were collected for the MMP protein at room temperature, in the presence and absence of the inhibitor AHA, resolving broad, weak transitions in the 400–600 nm (15 000–24 000  $\text{cm}^{-1}$ ) region with extinction coefficients of the order of  $\approx 100 \text{ M}^{-1} \text{ cm}^{-1}$ , which were relatively insensitive to AHA addition. The inferred weak extinction coefficient (50 and 150  $\text{M}^{-1} \text{ cm}^{-1}$ ) suggests that both Co<sup>2+</sup> sites of the protein are either 5 or 6-coordinate<sup>74–85</sup> as tetrahedral complexes display significantly larger values  $\epsilon \geq 150 \text{ M}^{-1} \text{ cm}^{-1}$ .<sup>74,85–93</sup> This includes literature data from Co substituted MMPs: MMP-1,<sup>69</sup> which has a tetrahedral catalytic site,<sup>94</sup> exhibits an intense band with  $\epsilon_{580} \approx 1000 \text{ M}^{-1} \text{ cm}^{-1}$ , whereas MMP-12, which has an octahedral catalytic site,<sup>15</sup> shows a weaker band with  $\epsilon_{545} \approx 80 \text{ M}^{-1} \text{ cm}^{-1}$ .






Fig. 6 (a) Electronic absorption spectra of  $\text{Co}^{2+}$  substituted MT1-MMP. The dashed line represents an estimate of the scattering background due to protein aggregation. (b) Corresponding low temperature MCD spectrum (1.8 K, 7 T). (c) With AHA inhibitor. The red dashed lines represent a fitting of the spectra assuming eight bands modeled in terms of a Gaussian profile. Individual bands are colored green (catalytic), blue (structural) and grey (uncertain). See also ESI,† S7.

Note that owing to the large scattering background seen in all samples, presumably resulting from partial enzyme aggregation, it is difficult to estimate with confidence the extinction coefficient or the effect of the inhibitor (Fig. 6a).

To refine this picture, low temperature MCD of  $\text{Co}^{2+}$ -substituted MT1-MMP was performed. These measurements identify multiple spin-allowed d-d transitions consistent with two or more protein-bound  $\text{Co}^{2+}$  ions (Fig. 6b). The profile could be modeled in terms of eight transitions. The addition of the inhibitor AHA was used to assign these transitions to either the catalytic site or the structural site; with the latter not being influenced by the binding of AHA (Fig. 6c). Bands 1–4 are all modified by the inhibitor and are thus assigned to the catalytic site: band 1 (17 200) band 2 (18 000) are significantly diminished or completely lost upon inhibitor binding whereas band 3 (20 000) decreases in intensity by 50% and is shifted to the red (500  $\text{cm}^{-1}$ ), and band 4 doubles in intensity (its position is not well defined in the non-inhibited form). Bands 5–8 are unchanged and thus assigned to the structural site (see ESI,† S7). It is noted that the structural site should also have some contribution in the 17 000–21 000  $\text{cm}^{-1}$  region and thus the fitted bands should only be assigned dominantly to one species

or the other. The electronic transitions observed represent the highest spin-allowed d-d transition of  $\text{Co}^{2+}$ : *i.e.* transitions between electronic states derived from the ground state  $^4\text{F}$  and excited state  $^4\text{P}$  terms.<sup>95</sup> For the free ion these levels are separated by 16 800  $\text{cm}^{-1}$  (15B), with the crystal/ligand field ( $10\text{Dq} < 5000\text{ cm}^{-1}$ ) tuning their exact positions (Fig. 7).<sup>95</sup> The bands assigned to the catalytic site in its uninhibited form best resemble those seen for 5 coordinate  $\text{Co}^{2+}$  complexes. Such complexes typically resolve two MCD features of negative ellipticity, derived from the splitting of the  $^4\text{P}$  term, here split by  $\approx 2500\text{ cm}^{-1}$ , supporting the assignment of bands 1–2 to  $^4\text{A}_2'(\text{F}) \rightarrow ^4\text{A}_2'(\text{P})$  and band 3 to  $^4\text{A}_2'(\text{F}) \rightarrow ^4\text{E}''(\text{P})$ .

The induction of MCD signals as a function of the temperature and applied field provides further support for this assignment.<sup>66,96,97</sup> The MCD C-term activity of  $\text{Co}^{2+}$  complexes is dependent on the ordering and separation of the two Kramers doublets that describe its ground magnetic spin state. In the instance where the separation is large, only one Kramers state is populated at cryogenic temperatures (0–20 K) and thus the induction of the MCD signal – described by its magnetization curve – is temperature invariant (the magnetization curves overlay). In contrast, if the separation is small, the relative populations of the two Kramers states will significantly vary as a function of temperature ( $< 100\text{ cm}^{-1}$ ) and as such its magnetization curves will vary with temperature; a phenomenon called ‘nesting’. The separation between the two Kramers states is defined by the zero-field splitting of the complex, which is defined by the parameter  $D$ . For  $\text{Co}^{2+}$  complexes the zero-field splitting comes about due to spin-orbit coupling (SOC) and its magnitude broadly correlates with the coordination number.<sup>66,96,97</sup> For tetrahedral complexes, the singlet ground electronic state ( $^4\text{A}_2$ ) is not strongly affected by SOC, whereas for octahedral complexes, the orbitally degenerate ground electronic state will split (to 1st order) due to the SOC mechanism; 5 coordinate complexes fall in between, with the SOC mechanism operating to 2nd order.<sup>97</sup> This sets up a hierarchy of  $D$  values which  $\text{Co}^{2+}$ -substituted enzymes typically follow:  $D$  is small (or negative) for tetrahedral complexes, moderate for 5 coordinate complexes and large for octahedral complexes, although there is significant overlap within these three ligand fields.<sup>66,96,97</sup>

Magnetization curves for these two bands (2 and 3) assigned to the catalytic state show nesting behavior consistent with a fine structure splitting value of approximately  $D = +25\text{ cm}^{-1}$ , and thus consistent with a 5 and 4 coordinate  $\text{Co}^{2+}$  complex. We note that band 1 has a non-physical magnetization curve presumably due to the overlap with another unresolved feature (*i.e.* structural site). It is less clear what band 4 represents. This band does not display the same field and temperature dependence lacking the nesting behavior of bands 2 and 3, suggesting a large, positive fine structure value ( $D > +100\text{ cm}^{-1}$ ). This simple, weak feature may represent a second population of the catalytic site in which it adopts an octahedral coordination with a  $^4\text{T}_{1g}(\text{F}) \rightarrow ^4\text{T}_{1g}(\text{P})$  transition. The presence of both these signals would then suggest that the resting state solvation of the  $\text{Co}^{2+}$  substituted enzyme is best described in terms of a dynamic 1st coordination sphere with two or three water molecules.






Fig. 7 Weak field splitting diagrams for a high spin  $d^7$  ion in a: (i) tetrahedral ( $T_d$ ), (ii) trigonal bipyramidal, (iii) and octahedral field. The highest spin allowed transition(s) ( $4F \rightarrow 4P$ ) is marked by the green and red arrows.

Whether both the front and back waters can bind independently of each other in a 5 coordinate geometry, or if instead there is a preferred solvation complex in the 5-coordinate form cannot be deduced from this data.

Upon binding of the inhibitor, the spectrum collapses into a doublet centered at  $19624 \text{ cm}^{-1}$ , although a shoulder may be present at  $18000 \text{ cm}^{-1}$ , which could be an underlying structural site signal. This feature shows no nesting behavior ( $D > 130 \text{ cm}^{-1}$ ), suggesting that the catalytic site with the inhibitor bound is best described in terms of an octahedral coordination. Both bands are assigned to a single complex, with the splitting due to a lowering of perfect octahedral symmetry. This requires the inhibited active site to have one water ligand. It is not clear whether the additional water binds on the front or back face of the complex (Fig. 8).

### 3.5 Dynamic interactions of auxiliary waters: EPR of $\text{Co}^{2+}$ -MT1-MMP

The above magnetic-optical analysis was refined using EPR. Fig. 9 shows CW X-band and pulse Q-band EPR spectra of the Co-substituted enzyme with and without AHA. The EPR signal at  $g \approx 4.3$  is indicative of  $\text{Co}^{2+}$  complex(es) with large positive zero-field splitting ( $D > +1 \text{ cm}^{-1}$ ), *i.e.* the magnetic ground state is  $M_S = |\pm\frac{1}{2}\rangle$ .<sup>68,98</sup> Temperature-dependent data shown in the ESI,<sup>†</sup> S7 confirm this assignment. The low-field signal consists of a broad feature with no resolved hyperfine structure and a second, relatively narrow feature, with an additional splitting. These two components show different temperature and power dependencies, with the broad signal saturating more readily (see ESI,<sup>†</sup> S7). The eight-line hyperfine pattern, which originates from the interaction with the  $^{59}\text{Co}$  nucleus ( $I = 7/2$ ), is often obscured at X-band (and higher frequencies) due to the effects of  $g$ - and  $D$ -strain.<sup>68</sup> The ground state




Fig. 8 Magnetization curves for the fitted bands for both the uninhibited (a and b) and inhibited (c and d) enzyme. Experimental parameters: temperatures 1.8, 5, 10, 20 K; magnetic fields 0, 1, 3, 5, 7 T.

assignment suggests that both Co sites of the protein are either pentacoordinated or octahedrally coordinated, consistent with MCD data described above (see also ESI,<sup>†</sup> S7).<sup>68</sup> The small signal at  $g = 2$  ( $B_0 \approx 340 \text{ mT}$  at X-band) is part of the baseline






Fig. 9 (A) CW X-band and (B) pulse Q-band EPR spectra for non-inhibited (black lines) and AHA-inhibited (red lines) MT1-MMP samples. X-band:  $T = 10$  K,  $\nu_{mw} = 9.649$  GHz; Q-band:  $T = 4.7$  K,  $\nu_{mw} = 34.032$  GHz for the non-inhibited and  $T = 4$  K,  $\nu_{mw} = 33.960$  GHz for the inhibited sample.

(resonator) and another background signal (adventitious  $\text{Fe}^{3+}$ ) observed at  $g = 4.33$  ( $B_0 = 159$  mT at X-band) varied from batch to batch. Inhibition of the enzyme with AHA changes the EPR line shape, indicating that the broad signal envelope represents (at least in part) the catalytic site, as the structural site is not expected to change upon inhibition. Interestingly, the hyperfine splitting observed is unaffected by inhibition, suggesting that this may be solely associated with the structural site. We note however that the hyperfine structure was not readily observed in all samples. The line shape of the main component indicates that the  $\text{Co}^{2+}$  ion has an approximately axial ZFS tensor ( $E/D \approx 0.1$ ). The rhombicity of the signal increases ( $E/D \approx 0.13$ ) upon AHA binding. Although a small  $E/D$  is usually thought to be reflective of octahedral coordination, in our case owing to high level symmetry (see Section 3.5 Fig. 11) we do not consider this parameter to give a definitive assessment of the coordination number.<sup>68</sup>

Subsequently pulse double resonance EPR experiments<sup>71</sup> were performed to directly assess the number of water ligands that bind at the catalytic  $\text{Co}^{2+}$  ion and to examine whether these are displaced by AHA. Davies  $^1\text{H}$ -ENDOR measurements show that there is at least one auxiliary water ligand in both the inhibited and non-inhibited state, with hyperfine coupling ( $A_{\text{dip}}$ ) of about 3 MHz typical for aqueous transition metal complexes.<sup>99,100</sup> It has a 'Pake-like' pattern indicative of a dipolar-coupled species (sitting perpendicular to the principal axis of the  $D$  tensor) that is lost upon deuteration. Both properties are only consistent with the presence of one or more water molecules in the 1st coordination sphere. These results immediately

imply that the AHA form of the cofactor is 6 coordinate, with three His ligands, two ligands from the inhibitor and 1 auxiliary water, in agreement with MCD data. A second, more strongly coupled water, is resolved by  $^2\text{H}$ -ESEEM/HYSCORE (see Fig. 10B). The observed hyperfine coupling of 1.5 MHz for  $^2\text{H}$  corresponds to  $A_{\text{obs}} \approx 9.8$  MHz for  $^1\text{H}$  due to the difference in the gyromagnetic ratios. We reason that the signal is too broad to be readily observed in the corresponding  $^1\text{H}$ -ENDOR experiment. Indeed we encountered a similar situation for the Mn/Fe cofactor of the R2lox protein.<sup>101</sup> The hyperfine coupling of this 1st coordination sphere water is approximately the same as observed earlier for the Zn finger protein Transcription Factor IIIA<sup>98</sup> and is assigned to the catalytic water. These results imply that the cofactor must be at least 5 coordinate in the non-inhibited state, with three His ligands, the polarized/catalytic water and at least 1 auxiliary water. We find that the 1.5 MHz signal is lost upon AHA binding (see Fig. 10C), replaced by a smaller coupling of 1.1 MHz, presumably the OH of the AHA. As the 1.5 MHz coupling is completely abolished, AHA is bound to all catalytic sites at this concentration. One further observation can be made from this dataset. A non-exchangeable proton signal with a splitting of 3.4 MHz is also resolved in the  $^1\text{H}$ -ENDOR spectrum of the non-inhibited sample; this signal is not lost upon deuteration. It is likely derived from the non-exchangeable proton(s) of the histidine ligands. This signal is however lost upon binding of AHA, suggesting that the ligand field of the catalytic  $\text{Co}^{2+}$  changes upon binding of the inhibitor. This final result supports the notion that the non-inhibited state is different




Fig. 10 (A) Q-band  $^1\text{H}$ -ENDOR spectra recorded at the field position  $B = 650$  mT for non-inhibited (black line) and AHA-inhibited (red line) samples in  $\text{H}_2\text{O}$  buffer (upper two traces) and after deuteration (lower traces); Q-band  $^2\text{H}$ -HYSCORE spectra of the (B) non-inhibited and (C) AHA-inhibited samples.



from the inhibited state, *i.e.* 5-coordinate, in agreement with MCD data. However as with the MCD measurements, EPR results do not show how the auxiliary water(s) binds in either the non-inhibited or inhibited state.

### 3.6 QM/MM modeling of the structural and active site of MT1-MMP

To further explore the role of the auxiliary water molecules during catalysis, QM/MM calculations were performed on a set of plausible structural models A–K (see ESI,† S8–S10 for detailed results and discussion). For selected models, the QM/MM optimized geometries of catalytic zinc coordination spheres with coordination numbers 4, 5 and 6 are shown in Fig. 11(C, E, and H). In addition, structural site models (A, B) and catalytic site models with extra water molecules in the second coordination shell (between Glu240 and the nucleophilic water) were examined (see ESI,† S8–S10). As expected, in tetrahedral models the single water ligand that binds to the metal ion also interacts with the nearby Glu240, and thus represents the nucleophilic water ( $W_n$ ) of the reaction mechanism. All 5-coordinate models contain the same water ligand ( $W_n$ ), and a second water that binds on the back face of the cofactor ( $W_b$ ), presumably because this allows for a hydrogen bonding interaction with the Pro259 residue. By definition, in the 6-coordinate models all three water molecules act as ligands ( $W_n$ ,  $W_b$ , and  $W_f$  on the front face of the cofactor).


The validity of these models was tested by comparing the calculated  $D$  value for each model with experimental values determined from MCD measurements (Table 1). As expected, the tetrahedral models (C, D) yield  $D$  values of the wrong sign and magnitude and can thus be discarded. One 5-coordinate model (E), in which  $W_n$  directly interacts with Glu240 yields a positive intermediate  $D$  value ( $+33\text{ cm}^{-1}$ ) in agreement with the dominant species observed by MCD. The other 5-coordinate

**Table 1** Zero-field splitting parameters ( $\text{cm}^{-1}$ ) calculated for the QM/MM optimized structures for models C–K (see text)

	CASSCF		NEVPT2	
	$D$	$E/D$	$D$	$E/D$
C	+11.8	0.27	+10.0	0.28
D	−16.8	0.10	−14.2	0.11
E	+39.1	0.01	+33.4	0.04
F	−20.3	0.30	±16.2	0.33
G	−27.3	0.12	−23.3	0.10
H	+119.2	0.07	+110.5	0.10
I	+96.1	0.19	+84.0	0.21
J	−22.2	0.29	−18.9	0.28
K	+89.2	0.29	±83.2	0.33
Exp. (native)	$D = +24.5\text{ cm}^{-1}$ ; $E/D = 0.10$			
Exp. (inhibited)	$D > +100\text{ cm}^{-1}$ ; $E/D = 0.13$			

models in which an additional water is located between  $W_n$  and Glu240 (F and G) yield negative  $D$  values and are thus not supported. Finally, the 6-coordinate models (H, I) yield large positive  $D$  values, larger than  $80\text{ cm}^{-1}$ . These models could therefore explain the second species that may be present in the MCD data. We note that other calculated magnetic parameters (*e.g.*  $^{59}\text{Co}$  and  $^{14}\text{N}$  hyperfine constants) were not discriminatory in terms of coordination/solvation number assignment.

We considered two further computational models (J, K) to investigate how auxiliary water interacts with the cofactor in the presence of bound AHA: model J does not include an additional first coordination sphere (auxiliary) water, whereas model K does. The hydroxamate anion ( $\text{CONHO}^-$ ) binds bidentately to the catalytic  $\text{Zn}^{2+}$  ion leading to a distorted trigonal-bipyramidal geometry around the metal, and it also forms a hydrogen bond with the carboxylate group of Glu240. The  $-\text{NH}-$  group forms another hydrogen bond with the carbonyl oxygen of Ala200, and van der Waals interactions and hydrophobic contacts play a



**Fig. 11** QM/MM optimized structures: coordination spheres of zinc at the uninhibited (C, E and H) and inhibited (J and K) catalytic site. Color code: carbon in green, nitrogen in blue, oxygen in red, hydrogen in white, and zinc in yellow.



critical role in stabilizing the inhibitor-enzyme complex.<sup>102</sup> In the QM/MM optimized geometry for model K, water binds only to the front face ( $W_f$ ). Comparison between computed and experimental MCD parameters shows that, as expected, model J is inconsistent with MCD data yielding a small negative  $D$  value. In contrast, structure K is consistent with the experimentally observed  $D$  value, *i.e.*  $>100 \text{ cm}^{-1}$ , derived from the MCD measurements and is in agreement with ENDOR results that showed the AHA complex has one first coordination sphere water. Structure K represents a genuine octahedral complex, with a water ligand stabilizing the bidentate ligation of the AHA. Thus all magneto-optical and magnetic resonance data presented above can be interpreted as follows:

(1) the solvation of the non-inhibited state is such that the Co/Zn ion is 5-coordinate (with only the  $W_b$  auxiliary water bound) which may be in equilibrium with a 6-coordinate population (with both auxiliary waters bound);

(2) the solvation of the inhibited state is such that the Co/Zn ion has one auxiliary water bound ( $W_f$ ) rendering the complex 6-coordinate.


Finally it should be emphasized that QM/MM geometry optimizations with  $\text{Co}^{2+}$  instead of  $\text{Zn}^{2+}$  converged to qualitatively

identical structures with a maximum absolute difference in bond length of  $0.18 \text{ \AA}$  (ESI,† S9).

## 4. Conclusions – implications for the mechanism

Our study provides new criteria for the mechanism of MMPs, modelling the first product state of the reaction, which has thus far only been accessed theoretically. In conjunction with the ground breaking study of Bertini *et al.*,<sup>15</sup> our study completes the reaction cycle and provides a chemical basis for C-terminus loss and the role that auxiliary/solvent water plays in this key reaction step. A complete reaction cycle of MMPs is described below and summarized in Fig. 12.

We favour a resting state structure that has at least one additional, non-catalytic water molecule ( $W_b$ , Fig. 12a). A third water ligand ( $W_f$ ) may also associate with the  $\text{Zn}^{2+}$  rendering the site octahedral. The dynamic nature of the solvation sphere – under physiological conditions – is not surprising and has literature precedent.<sup>8,23</sup> Importantly, we find that  $W_b$  more readily associates with the metal site than  $W_f$ . In all 5-coordinate DFT



**Fig. 12** Complete reaction cycle for MMPs including the sequence of steps involved in product release and the role of auxiliary/solvent water in this process. Structures (a, resting), (g and h) represent intermediates trapped in the Bertini study.<sup>15</sup> Structures (b) and (c) show the peptide binding and cleavage steps. Structure (d) represents the 1st product state of the reaction following peptide cleavage, developed in this study. Structures (e) and (f) show two possible resolution pathways, with only (e) leading to C-fragment loss.



models the second solvating water is  $W_b$  rather than  $W_f$ , presumably because  $W_b$  forms an H-bond to the second sphere Pro259 residue, whereas no such interaction with the protein is available for  $W_f$ . Both waters are displaced by the bulky substrate, which is found to coordinate in a bidentate fashion leading to the gem-diol intermediate (Fig. 12b and c). Following the cleavage of the peptide backbone the first predicted intermediate contains a newly formed C-terminus of one product fragment coordinating the  $Zn^{2+}$  as an asymmetric bidentate ligand (Fig. 12d). The bound carboxylate is stabilized by two interactions: (i) an H-bond between the  $\alpha$ -oxygen of the carboxylate and transiently protonated Glu240; and (ii) an H-bond to the  $\beta$ -oxygen of the carboxylate and an auxiliary water. Both these structural elements are found in the crystal structure we report here, with the auxiliary water bound on the front face ( $W_f$ ). Our structure deviates from the original computational proposal<sup>7</sup> in two important ways:

(1) The position of the Glu240 prohibits it from forming a bidentate H-bonding network to the amine product, as is proposed in the gem-diol intermediate.

Instead, we can model a monodentate H-bonding bridge between the two protein fragments. We speculate that, for this step in the cycle, an H-bonding interaction involving only the transiently protonated oxygen of the Glu240 would assist the subsequent proton transfer to the amine fragment as the tunneling distance is significantly smaller.

(2) The structure includes a second water ( $W_b$ ) which is also within H-bonding distance to the  $\alpha$ -oxygen of the carboxylate, further participating in stabilizing the asymmetric carboxylate binding motif.

We suspect that this water represents the water used as the nucleophile ( $W_n$ ) in the next reaction cycle as it is uniquely placed to displace the  $\alpha$ -oxygen of the product carboxylate. We speculate that the trigger for this event is the proton movement to the amine. Upon proton transfer,  $W_b$  moves within the coordination sphere of the  $Zn^{2+}$  (approx. 2 Å) to replace the lost H-bonding network between the  $\alpha$ -oxygen of the product and the Glu240. Simultaneously it may also gain an H-bond to the amine. At this point the water can displace the  $\alpha$ -oxygen forming the first experimentally characterized intermediate of the reaction, a mono-dentate 5-coordinate complex reported by Bertini and coworkers (Fig. 12g). This structure also exhibits a favourable H-bonding network between both product fragments facilitated by the incoming/relocated  $W_b$  and the Glu240. The mono-dentate C-terminus fragment is then released from the  $Zn^{2+}$  site, perhaps in competition with solvent, *i.e.* water binding on the back face, as seen in our resting state models (Fig. 12h). We note though that such a water molecule was not observed in the Bertini structure.<sup>15</sup> Nevertheless, carboxylate loss would strengthen the  $Zn^{2+}$  water ( $W_n$ ) interaction, shortening the  $W_n$ - $Zn^{2+}$  bond and disrupting its interaction with the amine. The amine, which at this point only weakly associates with the Glu240 (*via* H-bonding) is then also released.

The above sequence suggests that the C-fragment loss can be short-circuited slowing enzymatic turnover. Following proton transfer to the amine destabilizing the Zn-carboxylate complex,

the solvation sphere can respond in more than one way. Instead of  $W_b$  moving to restore the H-bonding network involving the Glu240 as described above (Fig. 12e),  $W_f$  could instead directly ligate the  $Zn^{2+}$  ion rendering the complex 6-coordinate, thus preventing the release of the carboxylate (Fig. 12f). This is indeed what we observe for the Co enzyme inhibited with AHA – an additional water binds on the front face rendering the complex 6-coordinate. Presumably both re-solvation pathways are in equilibrium, however we suspect that  $W_f$  binding is more likely to occur for the  $Co^{2+}$  enzyme as opposed to the native  $Zn^{2+}$  form, owing to the higher coordination number preference of  $Co^{2+}$ . This simple rationale would then explain the slower turnover of the  $Co^{2+}$  enzyme. Thus, the solvation and inhibition of the cofactor *via* small synthetic molecules are likely interrelated providing another crucial element needed for understanding the affinity of inhibitors of MMPs and their rational design. The strategy would be to ensure that the inhibitor mimics substrate/solvent interactions, either by replicating 1st solvation sphere interactions, or by the inclusion of functional groups which can replace the 1st solvation shell and its H-bonding to the protein surface. It is less clear how solvent/substrate interactions can be exploited toward selective inhibition of MMPs. This forms ongoing work of our laboratory.

## Conflicts of interest

There are no conflicts of interest to declare.

## Acknowledgements

Andreas Göbels and Dr Eckhard Bill are gratefully acknowledged for the acquisition of MCD spectra. We thank the staff of BESSYII (Helmholtz-Zentrum Berlin, Germany) for their help during the diffraction data collection. Financial support was provided by the Max Planck Gesellschaft and the Cluster of Excellence RESOLV (EXC 1069) funded by the Deutsche Forschungsgemeinschaft. I. S. is supported by the Binational Science Foundation (BSF) and Israel Science Foundation (ISF). I. S. and M. H. are also supported by the ERC Advanced Grant 695437 THz-Calorimetry. M. G. is an Awardee of the Weizmann Institute of Science National Postdoctoral Award Program for Advancing Women in Science and a recipient of an A. v. Humboldt Fellowship. N. C. acknowledges the support of the Australian Research Council: Future Fellowship (FT140100834). Open Access funding provided by the Max Planck Society.

## Notes and references

- M. Kamioka, T. Ishibashi, H. Ohkawara, R. Nagai, K. Sugimoto, H. Uekita, T. Matsui, S. I. Yamagishi, K. Ando, T. Sakamoto, N. Sakamoto, Y. Takuwa, I. Wada, M. Shiomi, Y. Maruyama and Y. Takeishi, *J. Cell. Physiol.*, 2011, **226**, 1554–1563.
- P. A. Eisenach, P. C. de Sampaio, G. Murphy and C. Roghi, *J. Biol. Chem.*, 2012, **287**, 11533–11545.



- 3 S. Pahwa, M. J. Stawikowski and G. B. Fields, *Cancers*, 2014, **6**, 416–435.
- 4 K. B. Hotary, E. D. Allen, P. C. Brooks, N. S. Datta, M. W. Long and S. J. Weiss, *Cell*, 2003, **114**, 33–45.
- 5 S. Gupta and V. Patil, in *Matrix Metalloproteinase Inhibitors*, ed. S. P. Gupta, Springer Basel, 2012, vol. 103, ch. 2, pp. 35–56.
- 6 R. E. Vandenbroucke and C. Libert, *Nat. Rev. Drug Discovery*, 2014, **13**, 904–927.
- 7 V. Pelmeshnikov and P. E. M. Siegbahn, *Inorg. Chem.*, 2002, **41**, 5659–5666.
- 8 E. Decaneto, S. Suladze, C. Rosin, M. Havenith, W. Lubitz and R. Winter, *Biophys. J.*, 2015, **109**, 2371–2381.
- 9 L. L. Johnson, A. G. Pavlovsky, A. R. Johnson, J. A. Janowicz, C.-F. Man, D. F. Ortwine, C. F. Purchase II, A. D. White and D. J. Hupe, *J. Biol. Chem.*, 2000, **275**, 11026–11033.
- 10 R. L. Stein and M. Izquierdomartin, *Arch. Biochem. Biophys.*, 1994, **308**, 274–277.
- 11 B. Arza, M. De Maeyer, J. Felez, D. Collen and H. R. Lijnen, *Eur. J. Biochem.*, 2001, **268**, 826–831.
- 12 N. Díaz and D. Suárez, *J. Phys. Chem. B*, 2008, **112**, 8412–8424.
- 13 T. Vasilevskaya, M. G. Khrenova, A. V. Nemukhin and W. Thiel, *J. Comput. Chem.*, 2015, **36**, 1621–1630.
- 14 B. W. Matthews, *Acc. Chem. Res.*, 1988, **21**, 333–340.
- 15 I. Bertini, V. Calderone, M. Fragai, C. Luchinat, M. Maletta and K. J. Yeo, *Angew. Chem., Int. Ed.*, 2006, **45**, 7952–7955.
- 16 A. Solomon, B. Akabayov, A. Frenkel, M. E. Milla and I. Sagi, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 4931–4936.
- 17 T. Crabbe, S. Zucker, M. I. Cockett, F. Willenbrock, S. Tickle, J. P. O'Connell, J. M. Scothern, G. Murphy and A. J. P. Docherty, *Biochemistry*, 1994, **33**, 6684–6690.
- 18 J. Cha and D. S. Auld, *Biochemistry*, 1997, **36**, 16019–16024.
- 19 C. Fernandez-Catalan, W. Bode, R. Huber, D. Turk, J. J. Calvete, A. Lichte, H. Tschesche and K. Maskos, *EMBO J.*, 1998, **17**, 5238–5248.
- 20 M. Grossman, D. Tworowski, O. Dym, M.-H. Lee, Y. Levy, G. Murphy and I. Sagi, *Biochemistry*, 2010, **49**, 6184–6192.
- 21 H. Nar, K. Werle, M. M. T. Bauer, H. Dollinger and B. Jung, *J. Mol. Biol.*, 2001, **312**, 743–751.
- 22 S. P. Gupta, *Chem. Rev.*, 2007, **107**, 3042–3087.
- 23 M. Grossman, B. Born, M. Heyden, D. Tworowski, G. B. Fields, I. Sagi and M. Havenith, *Nat. Struct. Mol. Biol.*, 2011, **18**, 1102–1108.
- 24 E. Decaneto, S. Abbruzzetti, I. Heise, W. Lubitz, C. Viappiani and M. Knipp, *Photochem. Photobiol. Sci.*, 2015, **14**, 300–307.
- 25 U. Neumann, H. Kubota, K. Frei, V. Ganu and D. Leppert, *Anal. Biochem.*, 2004, **328**, 166–173.
- 26 H. Ogata, E. Decaneto, M. Grossman, M. Havenith, I. Sagi, W. Lubitz and M. Knipp, *Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.*, 2014, **70**, 232–235.
- 27 W. Kabsch, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 125–132.
- 28 A. Vagin and A. Teplyakov, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 22–25.
- 29 P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L.-W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger and P. H. Zwart, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 213–221.
- 30 S. C. Lovell, I. W. Davis, W. B. Arendall, P. I. W. de Bakker, J. M. Word, M. G. Prisant, J. S. Richardson and D. C. Richardson, *Proteins*, 2003, **50**, 437–450.
- 31 B. Holmquist and B. L. Vallee, *Biochemistry*, 1973, **12**, 4409–4417.
- 32 A. I. Nalepa, J. J. Taing, A. Savitsky and M. Knipp, *Protein Expression Purif.*, 2013, **88**, 33–40.
- 33 E. Reijerse, F. Lendzian, R. Isaacson and W. Lubitz, *J. Magn. Reson.*, 2012, **214**, 237–243.
- 34 V. Krewald, M. Retegan, N. Cox, J. Messinger, W. Lubitz, S. DeBeer, F. Neese and D. A. Pantazis, *Chem. Sci.*, 2015, **6**, 1676–1695.
- 35 A. Tochowicz, K. Maskos, R. Huber, R. Oltenfreiter, V. Dive, A. Yiotakis, M. Zanda, W. Bode and P. Goettig, *J. Mol. Biol.*, 2007, **371**, 989–1006.
- 36 W. Humphrey, A. Dalke and K. Schulten, *J. Mol. Graphics*, 1996, **14**, 33–38.
- 37 A. D. MacKerell, D. Bashford, M. Bellott, R. L. Dunbrack, J. D. Evanseck, M. J. Field, S. Fischer, J. Gao, H. Guo, S. Ha, D. Joseph-McCarthy, L. Kuchnir, K. Kuczera, F. T. K. Lau, C. Mattos, S. Michnick, T. Ngo, D. T. Nguyen, B. Prodhom, W. E. Reiher, B. Roux, M. Schlenkrich, J. C. Smith, R. Stote, J. Straub, M. Watanabe, J. Wiórkiewicz-Kuczera, D. Yin and M. Karplus, *J. Phys. Chem. B*, 1998, **102**, 3586–3616.
- 38 W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey and M. L. Klein, *J. Chem. Phys.*, 1983, **79**, 926–935.
- 39 J.-P. Ryckaert, G. Ciccotti and H. J. C. Berendsen, *J. Comput. Phys.*, 1977, **23**, 327–341.
- 40 J. C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D. Skeel, L. Kalé and K. Schulten, *J. Comput. Chem.*, 2005, **26**, 1781–1802.
- 41 A. D. Becke, *J. Chem. Phys.*, 1993, **98**, 5648–5652.
- 42 P. J. Stephens, F. J. Devlin, C. F. Chabalowski and M. J. Frisch, *J. Phys. Chem.*, 1994, **98**, 11623–11627.
- 43 V. A. Rassolov, J. A. Pople, M. A. Ratner and T. L. Windus, *J. Chem. Phys.*, 1998, **109**, 1223–1229.
- 44 P. Sherwood, A. H. de Vries, M. F. Guest, G. Schreckenbach, C. R. A. Catlow, S. A. French, A. A. Sokol, S. T. Bromley, W. Thiel, A. J. Turner, S. Billeter, F. Terstegen, S. Thiel, J. Kendrick, S. C. Rogers, J. Casci, M. Watson, F. King, E. Karlsen, M. Sjøvoll, A. Fahmi, A. Schäfer and C. Lennartz, *THEOCHEM*, 2003, **632**, 1–28.
- 45 S. Metz, J. Kästner, A. A. Sokol, T. W. Keal and P. Sherwood, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2014, **4**, 101–110.
- 46 R. Ahlrichs, M. Bär, M. Häser, H. Horn and C. Kölmel, *Chem. Phys. Lett.*, 1989, **162**, 165–169.
- 47 W. Smith and T. R. Forester, *J. Mol. Graphics*, 1996, **14**, 136–141.
- 48 S. R. Billeter, A. J. Turner and W. Thiel, *Phys. Chem. Chem. Phys.*, 2000, **2**, 2177–2186.



- 49 F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2011, **2**, 73–78.
- 50 V. N. Staroverov, G. E. Scuseria, J. Tao and J. P. Perdew, *J. Chem. Phys.*, 2003, **119**, 12129.
- 51 F. Neese, *Inorg. Chim. Acta*, 2002, **337**, 181–192.
- 52 D. A. Pantazis, X.-Y. Chen, C. R. Landis and F. Neese, *J. Chem. Theory Comput.*, 2008, **4**, 908–919.
- 53 F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297–3305.
- 54 C. van Wüllen, *J. Chem. Phys.*, 1998, **109**, 392.
- 55 C. Angeli, R. Cimiraglia and J.-P. Malrieu, *J. Chem. Phys.*, 2002, **117**, 9138–9153.
- 56 C. Angeli, R. Cimiraglia and J.-P. Malrieu, *Theor. Chem. Acc.*, 2006, **116**, 434–439.
- 57 B. A. Hess, C. M. Marian, U. Wahlgren and O. Gropen, *Chem. Phys. Lett.*, 1996, **251**, 365–371.
- 58 W. R. English, B. Holtz, G. Vogt, V. Knäuper and G. Murphy, *J. Biol. Chem.*, 2001, **276**, 42018–42026.
- 59 A. M. Woskowicz, S. A. Weaver, Y. Shitomi, N. Ito and Y. Itoh, *J. Biol. Chem.*, 2013, **288**, 35126–35137.
- 60 R. Lang, M. Braun, N. E. Sounni, A. Noel, F. Frankenne, J. M. Foidart, W. Bode and K. Maskos, *J. Mol. Biol.*, 2004, **336**, 213–225.
- 61 H. Nagase and G. B. Fields, *Biopolymers*, 1996, **40**, 399–416.
- 62 I. Bertini, V. Calderone, M. Fragai, C. Luchinat, S. Mangani and B. Terni, *Angew. Chem., Int. Ed. Engl.*, 2003, **42**, 2673–2676.
- 63 L. Devel, F. Beau, M. Amoura, L. Vera, E. Cassar-Lajeunesse, S. Garcia, B. Czarny, E. A. Stura and V. Dive, *J. Biol. Chem.*, 2012, **287**, 26647–26656.
- 64 E. Nuti, D. Cuffaro, F. D'Andrea, L. Rosalia, L. Tepshi, M. Fabbi, G. Carbotti, S. Ferrini, S. Santamaria, C. Camodeca, L. Ciccone, E. Orlandini, S. Nencetti, E. A. Stura, V. Dive and A. Rossello, *ChemMedChem*, 2016, **11**, 1626–1637.
- 65 B. D. Belviso, R. Caliendo, D. Siliqi, V. Calderone, F. Arnesano and G. Natile, *Chem. Commun.*, 2013, **49**, 5492–5494.
- 66 J. A. Larrabee, C. M. Alessi, E. T. Asiedu, J. O. Cook, K. R. Hoerning, L. J. Klingler, G. S. Okin, S. G. Santee and T. L. Volkert, *J. Am. Chem. Soc.*, 1997, **119**, 4182–4196.
- 67 W. Maret and B. L. Vallee, *Methods Enzymol.*, 1993, **226**, 52–71.
- 68 B. Bennett, in *Metals in Biology: Applications of High-Resolution EPR to Metalloenzymes*, ed. G. Hanson and L. Berliner, Springer New York, New York, NY, 2010, pp. 345–370, DOI: 10.1007/978-1-4419-1139-1\_10.
- 69 S. P. Salowe, A. I. Marcy, G. C. Cuca, C. K. Smith, I. E. Kopka, W. K. Hagmann and J. D. Hermes, *Biochemistry*, 1992, **31**, 4535–4540.
- 70 I. Bertini, M. Fragai, Y. M. Lee, C. Luchinat and B. Terni, *Angew. Chem., Int. Ed.*, 2004, **43**, 2254–2256.
- 71 N. Cox, A. Nalepa, M.-E. Pandelia, W. Lubitz and A. Savitsky, in *Method Enzymol.*, ed. Z. Q. Peter and W. Kurt, Academic Press, 2015, vol. 563, pp. 211–249.
- 72 I. Bertini, V. Calderone, M. Cosenza, M. Fragai, Y. M. Lee, C. Luchinat, S. Mangani, B. Terni and P. Turano, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 5334–5339.
- 73 P. J. Hajduk, G. Sheppard, D. G. Nettlesheim, E. T. Olejniczak, S. B. Shuker, R. P. Meadows, D. H. Steinman, G. M. Carrera, P. A. Marcotte, J. Severin, K. Walter, H. Smith, E. Gubbins, R. Simmer, T. F. Holzman, D. W. Morgan, S. K. Davidsen, J. B. Summers and S. W. Fesik, *J. Am. Chem. Soc.*, 1997, **119**, 5818–5827.
- 74 B. L. Vallee and R. J. P. Williams, *Proc. Natl. Acad. Sci. U. S. A.*, 1968, **59**, 498–505.
- 75 F. Tonello, G. Schiavo and C. Montecucco, *Biochem. J.*, 1997, **322**, 507–510.
- 76 C. E. Sabel, R. Carbone, J. R. Dabous, S. Y. Lo and S. Siemann, *Biochem. Biophys. Res. Commun.*, 2011, **416**, 106–110.
- 77 J. A. Larrabee, C. H. Leung, R. L. Moore, T. Thamrongnawasawat and B. S. H. Wessler, *J. Am. Chem. Soc.*, 2004, **126**, 12316–12324.
- 78 R. Bicknell, G. R. Hanson, B. Holmquist and C. Little, *Biochemistry*, 1986, **25**, 4219–4223.
- 79 D. C. Brown and K. D. Collins, *J. Biol. Chem.*, 1991, **266**, 1597–1604.
- 80 J. B. Bjarnason and J. W. Fox, *Biochemistry*, 1983, **22**, 3770–3778.
- 81 S. L. Rose, L. C. Dickinson and E. W. Westhead, *J. Biol. Chem.*, 1984, **259**, 4405–4413.
- 82 G. S. Baldwin, A. Galdes, H. A. O. Hill, S. G. Waley and E. P. Abraham, *J. Inorg. Biochem.*, 1980, **13**, 189–204.
- 83 B. Holmquist, T. A. Kaden and B. L. Vallee, *Biochemistry*, 1975, **14**, 1454–1461.
- 84 W. Stocker, R. L. Wolz, R. Zwilling, D. J. Strydom and D. S. Auld, *Biochemistry*, 1988, **27**, 5026–5032.
- 85 B. Holmquist and B. L. Vallee, *J. Biol. Chem.*, 1974, **249**, 4601–4607.
- 86 B. L. Vallee, R. T. Simpson, R. D. Kobes, R. W. Erbe and W. J. Rutter, *Biochemistry*, 1971, **10**, 2466–2470.
- 87 W. Maret, I. Andersson, H. Dietrich, H. Schneiderbernlöhr, R. Einarsson and M. Zeppezauer, *Eur. J. Biochem.*, 1979, **98**, 501–512.
- 88 A. J. Sytkowski and B. L. Vallee, *Biochemistry*, 1978, **17**, 2850–2857.
- 89 S. A. Latt and B. L. Vallee, *Biochemistry*, 1971, **10**, 4263–4270.
- 90 F. A. Cotton and R. H. Soderberg, *J. Am. Chem. Soc.*, 1962, **84**, 872–873.
- 91 F. F. Morpeth and V. Massey, *Biochemistry*, 1982, **21**, 1318–1323.
- 92 M. Vasak and J. H. R. Kagi, *Proc. Natl. Acad. Sci. U. S. A.*, 1981, **78**, 6709–6713.
- 93 W. Maret, *Biochemistry*, 1989, **28**, 9944–9949.
- 94 I. Bertini, V. Calderone, L. Cerofolini, M. Fragai, C. F. G. C. Geraldès, P. Hermann, C. Luchinat, G. Parigi and J. M. C. Teixeira, *FEBS Lett.*, 2012, **586**, 557–567.
- 95 L. Banci, A. Bencini, C. Benelli, D. Gatteschi and C. Zanchini, *Structures versus Special Properties*, Springer



- Berlin Heidelberg, Berlin, Heidelberg, 1982, pp. 37–86, DOI: 10.1007/BFb0111296.
- 96 L. C. Kuo and M. W. Makinen, *J. Am. Chem. Soc.*, 1985, **107**, 5255–5261.
- 97 M. W. Makinen, L. C. Kuo, M. B. Yim, G. B. Wells, J. M. Fukuyama and J. E. Kim, *J. Am. Chem. Soc.*, 1985, **107**, 5245–5255.
- 98 C. J. Walsby, D. Krepkiy, D. H. Petering and B. M. Hoffman, *J. Am. Chem. Soc.*, 2003, **125**, 7502–7503.
- 99 N. Cox, W. Lubitz and A. Savitsky, *Mol. Phys.*, 2013, **111**, 2788–2808.
- 100 X. Tan, M. Bernardo, H. Thomann and C. P. Scholes, *J. Chem. Phys.*, 1993, **98**, 5147–5157.
- 101 H. S. Shafaat, J. J. Griese, D. A. Pantazis, K. Roos, C. S. Andersson, A. Popović-Bijelić, A. Gräslund, P. E. M. Siegbahn, F. Neese, W. Lubitz, M. Högbom and N. Cox, *J. Am. Chem. Soc.*, 2014, **136**, 13399–13409.
- 102 R. P. Verma, in *Matrix Metalloproteinase Inhibitors: Specificity of Binding and Structure-Activity Relationships*, ed. P. S. Gupta, Springer Basel, Basel, 2012, pp. 137–176, DOI: 10.1007/978-3-0348-0364-9\_5.

